Here are the stories from the S&P/ASX 200 (INDEXASX: XJO)(^AXJO) and Australian finance circles today. The ASX 200 is expected to open lower, according to futures trading in Sydney.

First, here are the data points:

Australian Dollar ($A) (AUDUSD): 71.81 US cents

Dow Jones (DJI) (Friday): down 2.24%

Oil (WTI): $US52.13 per barrel

Gold: $US1,254 per ounce

ASX 200 News

In economic news this week, National Australia Bank Ltd’s (ASX: NAB) business confidence and conditions data are due out on Tuesday along with the latest numbers on lending. Westpac Bank (ASX: WBC) will release its consumer confidence reading on Wednesday before Australian labour force data is put out on Thursday.

In sharemarket news, the a2 Milk Company Ltd (ASX: A2M) announced changes to its senior leadership team. The infant formula and milk producer announced Simon Hennessy, a2’s GM of International Development, and Michael Bracka, head of Business Development, will leave the company to retire and pursue other opportunities, respectively.

a2 Milk has been wildly successful at selling its a2 protein-only dairy products in Asia, the USA and Europe. It recently reported a jump in sales.

New Zealand auction website operator Trade Me Group Ltd (ASX: TME) announced CEO Jon Macdonald will continue as the CEO beyond the end of 2018. In June, Macdonald said he would step down from the top job but not until a smooth transition to a new CEO can be completed.

Technology company Integrated Research Limited (ASX: IRI) will change its sales structure and organisation. IRI has appointed Matt Glasner as Chief Commercial Officer and the resignation of Andrew Cuenin, President of the America’s and Global Alliances.

Integrated Research recently reported a weaker-than-expected sales result.

“On behalf of the Company, I want to congratulate Matt Glasner on his appointment to the role of CCO,” IRI CEO John Merakovsky said. “On behalf of the Company, I want to thank Andre Cuenin for his contribution to IR’s development and tireless efforts to grow sales revenue.”

Is it time to buy IRI shares? Don’t. Until you read this…

After searching through a market with over 2,000 shares, our lead expert investment analyst has narrowed it down to just 2 of his favourite rapid-growth shares in a FREE report to Rask Media readers.

Over the past five years, these two shares have gone from being 'tiny caps' to being serious contenders for the ASX 200.

Idea #1 is taking on the world, starting with the huge USA market. In a just a few short years the company has snatched market share away from rivals and is on its way to being the market leader.

Idea #2 uses a 'printer and cartridge' type model to get large and established customers: a) using their healthcare industry-leading product, b) paying for it again and again and again... so it's little wonder this company is tipped to grow at a rapid pace in 2019.

Access the free report by clicking here now. Absolutely no credit card or payment details required.

Disclaimer: Any information contained in this article is limited to general financial/investment advice only. The information has not taken into account your specific needs, goals or objectives, so please consider consulting a licenced and trusted adviser before acting on the information. Please read The Rask Group’s Financial Services Guide (FSG) for more information. This article is authorised by Owen Raszkiewicz of The Rask Group, which is a corporate authorised representative No. 1264179 of Strawman Pty Ltd (ACN: 610 908 211) (AFSL: 501 223).